Showing 1801-1810 of 2192 results for "".
- Concussion Effects May Linger More Than a Year After Return to Playhttps://practicalneurology.com/news/concussion-effects-may-linger-more-than-a-year-after-return-to-play/2469051/New research published in Neurology has found athletes’ brains may still not be fully recovered 1 year after being allowed to return to play. The study involved 24 college athletes with concuss
- Gene Therapy for Children Age 6 Months to 5 Years with Spinal Muscular Atrophy Type 2 Effective in Clinical Trialhttps://practicalneurology.com/news/gene-therapy-for-children-age-6-months-to-5-years-with-spinal-muscular-atrophy-type-2-effective-in-clinical-trial/2469042/Children age 6 months to 5 years with spinal muscular atrophy (SMA), treated with onasemnogene (AVXS-101; Zolgensma, Bannockburn, IL) are showing improvements in motor function. In the STRONG (NCT03381729) phase 1/2 clinical study, 1 of
- Children with Spinal Muscular Atrophy Who Were Treated With Single-Dose Gene Therapy Continue Making Clinical Gainshttps://practicalneurology.com/news/children-with-spinal-muscular-atrophy-who-were-treated-with-single-dose-gene-therapy-continue-making-clinical-gains/2469026/Children treated with single-dose gene replacement therapy (Zolgensma; Avexis, Bannockburn, IL) for spinal muscular atrophy (SMA) continue meeting development milestones in the phase 3 SPR1NT clinical trial (NCT03505099). Treatment was
- Parkinson’s IQ + You Events Provide Support for All Affected by the Disorderhttps://practicalneurology.com/news/parkinsons-iq-you-events-support-provide-support-for-all-affected-by-the-disorder/2468940/A series of events titled Parkinson’s IQ + You will be taking place at locations across the US throughout 2019 and 2020. These events are designed to help people with Parkinson's disease (PD) and their care partners manage the effects of PD, learn about research, and connect with local
- Zolgensma Approved and Available to Treat All Types of Spinal Muscular Atrophy in Babies Under Age 2 Yearshttps://practicalneurology.com/news/zolgensma-approved-and-available-to-treat-all-types-of-spinal-muscular-atrophy-in-babies-under-age-2-years/2468911/The Food and Drug Administration (FDA) has approved onasemnogene abeparvovac-xioi (Zolgensma; Avexis, Bannockburn, IL) for the treatment of all types of spinal muscular atrophy (SMA) in children under age 2 years. Approved indications for onasemnogene, an SMN gene-replacement therapy, include all
- Young Blood Plasma for Parkinson's Diseasehttps://practicalneurology.com/news/young-blood-plasma-causes-neurological-improvement-in-parkinsons-disease-patients/2468880/Results of a clinical trial that administered blood plasma from donors, age 18 to 25 years, into individuals with Parkinson's disease resulted in significant improvements in neurologic assessments. After 3 months, patients showed improvements in motor
- Early Treatment of Clinically Isolated Syndrome With Interferon ß-1b Shows Benefit Over a 15-Year Periodhttps://practicalneurology.com/news/early-treatment-of-clinically-isolated-syndrome-with-interferon-1b-shows-benefit-over-a-15-year-period/2468814/Patients with clinically isolated syndrome (CIS) who were treated with interferon ß-1b (IFN) show long term benefits of early treatment (initiation within 2 years of diagnosis.) After 15 years, patients who were treated upon diagnosis of CIS (n = 161) or within 2 years of diagnosis (n = 100
- Alemtuzumab Effective for Treatment of MS Over 8 Years of Follow Uphttps://practicalneurology.com/news/alemtuzumab-effective-for-treatment-of-ms-over-8-years-of-follow-up/2468817/After 8 years of treatment with alemtuzumab (Lemtrada; Sanofi, Bridgewater, NJ), patients treated with 3 or more courses of the drug had an annualized relapse rate (ARR) of 0.18%, 85% of patients have been free of relapses, and 70% of patients had stable or improved scores on the Expanded Disabil
- Targeted Thalamic Stimulation Superior at Modulating Epileptiform Activity in Individuals with Focal Epilepsyhttps://practicalneurology.com/news/targeted-thalamic-stimulation-superior-at-modulating-epileptiform-activity-in-individuals-with-focal-epilepsy/2484018/Study results published in Nature Communications demonstrated a reduction in cortical interictal epileptiform discharge (IED) and seizure frequency in individuals with drug-resistant focal epilepsy receiving treatment with targeted thalamic stimulation. According to the authors, these da
- Four-Year Clarity-AD Data Show Slower Clinical Decline with Leqembi Treatmenthttps://practicalneurology.com/news/four-year-clarity-ad-data-show-slower-clinical-decline-with-leqembi-treatment/2475914/According to new 48-month data from the Clarity-AD (NCT03887455) open-label extension (OLE) study presented at the 2025 meeting of the Alzheimer’s Association International Conference (AAIC), individuals with early Alzheimer disease (AD) who received continuous treatment with Leqembi (lecanemab-i